Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC

10.1002/cpdd.427

Saved in:
Bibliographic Details
Main Authors: Tan, Eng-Huat, Lim, Wan-Teck, Ahn, Myung-Ju, Ng, Quan-Sing, Ahn, Jin Seok, Tan, Daniel Shao-Weng, Sun, Jong-Mu, Han, May, Payumo, Francis C, Mckee, Krista, Yin, Wei, Credi, Marc, Agarwal, Shefali, Jac, Jaroslaw, Park, Keunchil
Other Authors: DEAN'S OFFICE (DUKE-NUS MEDICAL SCHOOL)
Format: Article
Language:English
Published: WILEY 2022
Subjects:
MET
Online Access:https://scholarbank.nus.edu.sg/handle/10635/218636
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: National University of Singapore
Language: English
id sg-nus-scholar.10635-218636
record_format dspace
spelling sg-nus-scholar.10635-2186362023-10-31T20:32:36Z Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC Tan, Eng-Huat Lim, Wan-Teck Ahn, Myung-Ju Ng, Quan-Sing Ahn, Jin Seok Tan, Daniel Shao-Weng Sun, Jong-Mu Han, May Payumo, Francis C Mckee, Krista Yin, Wei Credi, Marc Agarwal, Shefali Jac, Jaroslaw Park, Keunchil DEAN'S OFFICE (DUKE-NUS MEDICAL SCHOOL) DUKE-NUS MEDICAL SCHOOL Science & Technology Life Sciences & Biomedicine Pharmacology & Pharmacy ficlatuzumab NSCLC gefitinib lung adenocarcinoma non-small cell lung cancer CELL LUNG-CANCER ADVANCED SOLID TUMORS FACTOR RECEPTOR CLINICAL-SIGNIFICANCE SCATTER-FACTOR RESISTANCE MET MUTATIONS ERLOTINIB ADENOCARCINOMA 10.1002/cpdd.427 CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT 7 5 532-542 2022-04-07T09:30:27Z 2022-04-07T09:30:27Z 2018-06-01 2022-04-07T02:43:18Z Article Tan, Eng-Huat, Lim, Wan-Teck, Ahn, Myung-Ju, Ng, Quan-Sing, Ahn, Jin Seok, Tan, Daniel Shao-Weng, Sun, Jong-Mu, Han, May, Payumo, Francis C, Mckee, Krista, Yin, Wei, Credi, Marc, Agarwal, Shefali, Jac, Jaroslaw, Park, Keunchil (2018-06-01). Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT 7 (5) : 532-542. ScholarBank@NUS Repository. https://doi.org/10.1002/cpdd.427 21607648 https://scholarbank.nus.edu.sg/handle/10635/218636 en WILEY Elements
institution National University of Singapore
building NUS Library
continent Asia
country Singapore
Singapore
content_provider NUS Library
collection ScholarBank@NUS
language English
topic Science & Technology
Life Sciences & Biomedicine
Pharmacology & Pharmacy
ficlatuzumab
NSCLC
gefitinib
lung adenocarcinoma
non-small cell lung cancer
CELL LUNG-CANCER
ADVANCED SOLID TUMORS
FACTOR RECEPTOR
CLINICAL-SIGNIFICANCE
SCATTER-FACTOR
RESISTANCE
MET
MUTATIONS
ERLOTINIB
ADENOCARCINOMA
spellingShingle Science & Technology
Life Sciences & Biomedicine
Pharmacology & Pharmacy
ficlatuzumab
NSCLC
gefitinib
lung adenocarcinoma
non-small cell lung cancer
CELL LUNG-CANCER
ADVANCED SOLID TUMORS
FACTOR RECEPTOR
CLINICAL-SIGNIFICANCE
SCATTER-FACTOR
RESISTANCE
MET
MUTATIONS
ERLOTINIB
ADENOCARCINOMA
Tan, Eng-Huat
Lim, Wan-Teck
Ahn, Myung-Ju
Ng, Quan-Sing
Ahn, Jin Seok
Tan, Daniel Shao-Weng
Sun, Jong-Mu
Han, May
Payumo, Francis C
Mckee, Krista
Yin, Wei
Credi, Marc
Agarwal, Shefali
Jac, Jaroslaw
Park, Keunchil
Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC
description 10.1002/cpdd.427
author2 DEAN'S OFFICE (DUKE-NUS MEDICAL SCHOOL)
author_facet DEAN'S OFFICE (DUKE-NUS MEDICAL SCHOOL)
Tan, Eng-Huat
Lim, Wan-Teck
Ahn, Myung-Ju
Ng, Quan-Sing
Ahn, Jin Seok
Tan, Daniel Shao-Weng
Sun, Jong-Mu
Han, May
Payumo, Francis C
Mckee, Krista
Yin, Wei
Credi, Marc
Agarwal, Shefali
Jac, Jaroslaw
Park, Keunchil
format Article
author Tan, Eng-Huat
Lim, Wan-Teck
Ahn, Myung-Ju
Ng, Quan-Sing
Ahn, Jin Seok
Tan, Daniel Shao-Weng
Sun, Jong-Mu
Han, May
Payumo, Francis C
Mckee, Krista
Yin, Wei
Credi, Marc
Agarwal, Shefali
Jac, Jaroslaw
Park, Keunchil
author_sort Tan, Eng-Huat
title Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC
title_short Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC
title_full Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC
title_fullStr Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC
title_full_unstemmed Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC
title_sort phase 1b trial of ficlatuzumab, a humanized hepatocyte growth factor inhibitory monoclonal antibody, in combination with gefitinib in asian patients with nsclc
publisher WILEY
publishDate 2022
url https://scholarbank.nus.edu.sg/handle/10635/218636
_version_ 1781793042864275456